These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17680888)

  • 21. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
    Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.
    Volz TJ; Hanson GR; Fleckenstein AE
    Synapse; 2006 Nov; 60(6):474-7. PubMed ID: 16897727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
    Liu B; Dluzen DE
    Synapse; 2006 Oct; 60(5):354-61. PubMed ID: 16838362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity.
    Dluzen DE; McDermott JL
    Ann N Y Acad Sci; 2002 Jun; 965():136-56. PubMed ID: 12105091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-dependent effects of methamphetamine on VMAT-2.
    Rau KS; Truong JG; Wilkins DG; Fleckenstein AE; Hanson GR
    Ann N Y Acad Sci; 2006 Aug; 1074():154-9. PubMed ID: 17105913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of gender and the neurotrophin, BDNF, upon methamphetamine-induced neurotoxicity of the nigrostriatal dopaminergic system in mice.
    Dluzen DE
    Neurosci Lett; 2004 Apr; 359(3):135-8. PubMed ID: 15050682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
    Truong JG; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways.
    Bourque M; Liu B; Dluzen DE; Di Paolo T
    Psychoneuroendocrinology; 2011 Aug; 36(7):955-69. PubMed ID: 21236583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.
    Wilhelm CJ; Johnson RA; Lysko PG; Eshleman AJ; Janowsky A
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1142-51. PubMed ID: 15102929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen, testosterone, and methamphetamine toxicity.
    Dluzen DE; McDermott JL
    Ann N Y Acad Sci; 2006 Aug; 1074():282-94. PubMed ID: 17105924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the striatal dopaminergic neurotransmission in MEN2B mice with elevated cerebral tissue dopamine.
    Mijatovic J; Patrikainen O; Yavich L; Airavaara M; Ahtee L; Saarma M; Piepponen TP
    J Neurochem; 2008 Jun; 105(5):1716-25. PubMed ID: 18248620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of freezing and extraction upon striatal dopaminergic function.
    Dluzen DE
    J Neurosci Methods; 2011 May; 198(1):23-8. PubMed ID: 21392526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system.
    Dluzen DE; Mickley KR
    Pharmacol Biochem Behav; 2005 Jan; 80(1):27-33. PubMed ID: 15652377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced expression and capacity of the striatal high-affinity choline transporter in hyperdopaminergic mice.
    Parikh V; Apparsundaram S; Kozak R; Richards JB; Sarter M
    Neuroscience; 2006 Aug; 141(1):379-89. PubMed ID: 16675138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity.
    Dluzen DE; McDermott JL
    Ann N Y Acad Sci; 2004 Oct; 1025():205-20. PubMed ID: 15542719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Markers associated with testosterone enhancement of methamphetamine-induced striatal dopaminergic neurotoxicity.
    Buletko AB; Dluzen DE; McDermott JL; Darvesh AS; Geldenhuys WJ
    Neurotoxicol Teratol; 2012; 34(3):338-43. PubMed ID: 22521941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice.
    Dluzen DE; Gao X; Story GM; Anderson LI; Kucera J; Walro JM
    Exp Neurol; 2001 Jul; 170(1):121-8. PubMed ID: 11421589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex.
    Naudon L; Leroux-Nicollet I; Raisman-Vozari R; Botton D; Costentin J
    Synapse; 1995 Sep; 21(1):29-36. PubMed ID: 8525459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice.
    Myers RE; Anderson LI; Dluzen DE
    Neuropharmacology; 2003 Apr; 44(5):624-32. PubMed ID: 12668048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methamphetamine-induced selective dopaminergic neurotoxicity is accompanied by an increase in striatal nitrate in the mouse.
    Anderson KL; Itzhak Y
    Ann N Y Acad Sci; 2006 Aug; 1074():225-33. PubMed ID: 17105919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.